Although several PDGFR inhibitors are approved for clinical use in other cancer types, attempts at PDGFR inhibition in PC patients have so far been unsuccessful with no improvement in disease specific survival, despite robust pre-clinical results8, 9, 10. The gene discussed is PDGFRB; the disease is pachyonychia congenita.